Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D 2 -type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ( 1 H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed 1 H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ.
INTRODUCTION
At present, the antipsychotics (typical or atypical) are the only approved treatments for schizophrenia (SCZ). In many patients, psychotic symptoms are only partially responsive or completely unresponsive to antipsychotic drugs, 1 and there are currently no agents with proven efficacy for negative symptoms or persistent neurocognitive dysfunction. Even for subjects who respond well to treatments, existing medications are associated with significant cognitive, motoric or metabolic side effects that limit compliance. Thus, newer treatments for SCZ are desperately required.
All current treatments for SCZ function primarily by blocking D 2 -type dopamine receptors. 2 Alternative neurochemical theories focus on disturbances in brain glutamatergic pathways, including impairments in signaling at synaptic N-methyl-D-aspartate (NMDA)-type glutamate receptors (NMDARs; Figure 1 ). 3, 4 Approaches for normalization of glutamatergic function are currently under development. To date, promising results have been obtained with compounds such as glycine, D-serine, sarcosine 5 and glycine transport inhibitors 6 that target the glycine site of the NMDAR, and with N-acetylcysteine (NAC), a precursor compound for the amino acid cysteine in brain. 5 However, the slow rate of therapeutic development has led a group of leading experts from academia, government and PHARMA 7 to conclude that effectively translating findings from genetics and basic science into therapies will require the development of robust biomarkers and assessment of target engagement of experimental agents. 7 The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ( 1 H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine. We will also review 1 H MRS/ PET/SPECT work that has been performed using the ketamine challenge model in healthy subjects and discuss their pathophysiological implications. Preclinical and clinical evidence supporting a role for each particular component of the glutamatergic system in SCZ will be reviewed, followed by summaries of the relevant 1 H MRS and/or PET/SPECT literature. We will conclude with a discussion of how these neurochemical findings inform the glutamate hypothesis of SCZ and can enhance drug development of glutamatergic agents in SCZ.
GLUTAMATE AND THE NMDA RECEPTOR Background: evidence for NMDA receptor dysfunction in SCZ In initial studies with phencyclidine and ketamine in the early 1960s, it was noted that both agents produced positive, negative and cognitive symptoms of SCZ. 8, 9 These compounds induce symptoms by blocking neurotransmission at the NMDAR, suggesting an alternative model for pathogenesis in SCZ. Symptomatic effects of NMDAR blockade were better classified starting in the early 1990s in a series of ketamine challenge studies conducted in both normal volunteers and SCZ patients. [10] [11] [12] [13] In normal volunteers, positive, negative and cognitive symptoms were observed in similar proportions as in SCZ. NMDAR blockade also reproduces both the severity and type of thought disorder seen in SCZ with both, for example, being associated with high levels of poverty of speech, circumstantiality and loss of goal, and relatively low levels of distractive or stilted speech or paraphasias. 11 These data and others suggest that reduction in NMDA functioning within the brain could serve as a single unifying feature to account for the otherwise complex pattern of deficits observed in SCZ (see review in Kantrowitz and Javitt 4 ). The development of the glutamate hypothesis of SCZ, initially based in large part on the effects of phencyclidine, closely resembles the initial development of the dopamine hypothesis of SCZ, which was based in large part on observations of the psychotogenic effects of stimulant medications.
14 PET and SPECT later supported this hypothesis by indicating increased dopamine synthesis, [15] [16] [17] greater striatal amphetamine-stimulated dopamine release that is related to positive symptoms [18] [19] [20] and increased baseline occupancy of striatal dopamine D 2 receptors by dopamine that also predicts the response of positive symptoms to treatment with antipsychotic agents. 21 The negative symptoms and cognitive deficits of SCZ are thought to be related, at least in part, to a cortical dopamine deficit, as originally proposed by Weinberger 22 and Davis et al. 23 based on preclinical and other indirect data. PET studies of cortical dopamine D 1 receptors reported inconsistent results, [24] [25] [26] [27] and more direct examination of dopaminergic transmission in the cortex is currently underway.
A point of convergence of the dopamine and NMDA models is at the level of local regulation of presynaptic dopamine release. Within striatum and frontal cortex, presynaptic dopamine release is under control of intrinsic inhibitory GABAergic neurons that, in turn, are activated by NMDAR. In striatum, regulation of dopamine release appears to be modulated by GABA B receptors localized to presynaptic dopamine terminals. GABA release, in turn, is modulated by NMDAR located on GABA interneurons, with stimulation leading to increased GABA release. 28 Therefore, some of the initial imaging studies of the glutamatergic system sought to further validate the glutamate/NMDA model of SCZ by examining the effects of ketamine on dopamine transmission and receptors in healthy control subjects. 34 Clinical correlations were mixed. 30, 33, 34 One study used the D 2 /D 3 SPECT ligand [ 123 ] IBZM to study the effect of ketamine on amphetamine-induced dopamine release in striatum as measured by a change in D 2 /D 3 receptor availability 35 and reported a decrease in binding of [ 123 ] IBZM after amphetamine infusion and a significantly lower binding when the subjects received amphetamine under conditions of ketamine infusion. This finding lends further validity to the glutamate/NMDA model of SCZ, as the enhanced response to amphetamine resulting from ketamine in healthy subjects is similar to the exaggerated response to amphetamine seen in SCZ. [18] [19] [20] In addition, Narendran et al. 36 compared binding of the D 1 receptor PET ligand [ 11 C]NNC112 in chronic ketamine users and healthy control subjects, and reported higher D 1 receptor availability in the dorsolateral prefrontal cortex (DLPFC) of chronic ketamine users similar to what has been observed in SCZ. 24, 25 In summary, PET and SPECT studies testing the effects of NMDA blockade on dopaminergic indices in healthy subjects using ketamine alone found mixed results in striatum, [29] [30] [31] [32] [33] 35 but significant effects in cortex, consistent with prior rodent data. 37 However, strikingly similar results for amphetamine-induced dopamine release in individuals with SCZ and healthy subjects given acute ketamine 35 provide initial support for the glutamate/ NMDA hypothesis of SCZ. Nevertheless, direct, in vivo measurements of glutamatergic indices are necessary to translate preclinical and clinical findings into effective therapies. Although the development of PET and SPECT imaging of the glutamate system has lagged behind that of the dopamine system, MRS technologies have effectively been utilized to measure glutamatergic indices in vivo.
Glutamate and dopamine PET/SPECT

Glutamatergic
H MRS
Several studies have compared glutamatergic indices-namely glutamate (Glu), glutamine (Gln) or Glu þ Gln (Glx)-in the brains of individuals with SCZ with healthy control subjects using 1 H MRS. These findings are summarized below by brain region. Overall, there is a suggestion that glutamatergic levels are somewhat elevated in early-stage, drug-free patients, and decrease after treatment. Future 1 H MRS studies should focus on the longitudinal assessment of patients in the prodromal and/or drug-naive state and after conversion or treatment with medications in order to provide valuable information on the neurochemical signatures of these groups and potentially allow researchers to identify biomarkers of SCZ risk.
Notably, the synthesis of these data is complicated by a number of factors related to study heterogeneity, including different field strengths, description (for example, unmedicated, medicated, high risk) and number of subjects in each study, neurochemicals measured (that is, Glu, Glx and/or Gln, and whether they include GABA), spectral editing/fitting techniques, use of segmentation (that is, controlling for tissue composition) and matching (that is, confounds related to SCZ/healthy controls). This information for each 1 H MRS study cited herein that examined Glu, Glx or Gln is summarized in Table 1 . Several summary statements can be made. Namely, every study examined appeared to use a method of spectral fitting, which is important for quantification of neurochemical peaks. Segmentation provides more robust measurements when comparing across groups, but is not necessary for within-subject designs. Third, although Glu, Glx or Gln are all standard measures of glutamatergic neurochemistry, Glu itself is the most pure measure, and not all studies clearly indicated whether or not GABA was included in the Glx measure (that is, as opposed to only Glu and Gln), complicating the interpretation of findings. Finally, although most studies that compared across groups controlled for gender and age, several also controlled for additional characteristics, including education, IQ and/or parental education, although statistical comparisons were not always reported. Abbreviations: A, age; DN, drug-naive schizophrenia; DF, drug-free schizophrenia; ED, education; ET, ethnicity; Gln, glutamine; Glu, glutamate; Glx, Glu þ Gln; HC, healthy control; 1 H MRS, proton magnetic resonance spectroscopy; HR, high risk for schizophrenia; M, medicated schizophrenia; MRS, magnetic resonance spectroscopy; N, no; NA, not analyzed; O, occupation; PA, parental; PR, premorbid; PRESS, point-resolved spectroscopy; S, sex; SES, socioeconomic status; STEAM: stimulated echo acquisition mode; T, tobacco; Y, yes. a Groups were considered not matched if groups were statistically different. Otherwise, groups were considered matched whether or not formal statistical comparisons were performed. Many to all of these subjects were also studied after treatment with antipsychotic medications. Appears that Glu includes Gln and Glu. e These subjects had the 22q11 Deletion Syndrome. There were also 10 subjects with the 22q11 Deletion Syndrome who did not have SCZ. Not readily apparent from the manuscript whether these were drug-naive or drug-free subjects. Glutamate imaging in schizophrenia EMP Poels et al DLPFC. Most studies of glutamatergic indices in the DLPFC show no differences between patient and control groups in either medicated or unmedicated subjects, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] whereas some have shown either increases or decreases in medicated subjects. [48] [49] [50] [51] [52] [53] Longitudinal studies investigating the effect of treatment with antipsychotic medications on glutamatergic measures in DLPFC show either decreases or no change. 39, 42, 51 Finally, most of these studies report no significant relationships between glutamatergic measures in DLPFC and clinical/behavioral symptoms.
MPFC including ACC. It has consistently been reported that unmedicated patients have elevated glutamatergic levels in the medial prefrontal cortex (MPFC) compared with healthy control subjects, 47, [54] [55] [56] although one study reported no differences. 57 The pattern in medicated patients is less clear, although the majority of studies suggest that glutamatergic levels in medicated patients are similar to those in healthy control subjects. 40, 47, [58] [59] [60] [61] [62] [63] Longitudinal studies of subjects in unmedicated and medicated states are few in number and do not consistently support an effect of medications on glutamatergic indices. 56, 57, 62, 64, 65 In addition, studies investigating relationships between glutamatergic levels in the MPFC and clinical/behavioral symptoms have been mostly negative. Egerton et al. 66 investigated Glu levels in a group of firstepisode (FE) patients, most of whom were medicated. Patients in remission had lower levels of Glu in the anterior cingulate cortex (ACC) than nonremitted patients. In addition, across the whole sample, ACC Glu levels were associated with greater negative symptoms and worse global functioning. In contrast, Reid et al. 63 reported that Glx levels were associated with less negative symptoms in their sample.
Parietal and occipital lobe. It is difficult to draw conclusions about glutamatergic indices in this area because of the paucity of studies, as well as significant differences in regions of interest placement and patient populations. Some studies suggest abnormalities in glutamatergic levels in parietal or occipital cortex, 67-69 whereas others do not. 39, 43, 58, 59 Relationships between neurochemical indices and clinical measures are also inconsistent.
Temporal lobe. There are no patterns of glutamatergic abnormalities in the temporal lobe of patients with SCZ. 42, 45 One study also reports that treatment with antipsychotic medications may decrease levels of Glx. 42 Hippocampus/medial temporal lobe. Studies of glutamatergic levels in hippocampus are mostly negative, 48, 50, 61, [70] [71] [72] [73] although some have reported increased glutamatergic levels in chronic medicated patients. 41, 49, 68 One longitudinal study reported no effect of medication in this population, 65 although Glu, Gln and GABA were measured together and the region included hippocampus and temporal lobe. In addition, some investigations suggest relationships between glutamate levels and executive functioning 50 and global clinical state, 49 although these findings need to be replicated.
Thalamus. There seems to be no clear pattern of glutamatergic abnormalities in the thalamus. Patients are found to be either no different than control subjects, 38, 42, 46, 62, [73] [74] [75] have increased indices in some FE drug-naive patients 54, 56, 57 or have decreased indices in some high-risk populations. 72, 76 The effects of medication treatment are also mostly negative, 57, 62, 65 although one study reported a decrease in Gln levels after 30 months of treatment with antipsychotic medications. 56 Similarly, there do not appear to be relationships between glutamatergic levels in the thalamus and symptomatology.
Cerebellum. One study measured Glu and Glx levels in the cerebellum of a group of drug-naive prodromal and FE patients 77 and reported no difference in Glu or Glx levels between patients and healthy control subjects in this region. The effect of antipsychotic medication on glutamatergic levels in this region has not been investigated.
Basal ganglia. There seem to be no differences in glutamatergic indices between chronic medicated patients and healthy control subjects, 44, 78 although FE subjects demonstrated elevated Glx or Glu. 39, 77, 79 The results in high-risk or prodromal subjects are mixed, 75, 77 although a longitudinal study demonstrated that higher levels of Glu were observed in the psychosis transition group when compared with the nontransition group and healthy control subjects. 80 Another longitudinal study of antipsychoticnaive individuals with FE psychosis demonstrated that Glu levels in associative striatum decrease after 4 weeks of treatment with risperidone. 79 The majority of clinical correlations have not been significant.
H MRS studies with ketamine challenge
To further test the glutamate/NMDA hypofunction theory of SCZ, several investigations have examined the effect of ketamine on glutamatergic levels in the ACC, measured by 1 H MRS (Table 2 ). Stone et al. 81 scanned healthy subjects while receiving a ketamine infusion. Glutamatergic levels were measured by 1 H MRS before and after ketamine infusion. This study reported increased levels of Glu after ketamine infusion and observed a positive correlation between Glu levels after ketamine administration and score on the PANSS (Positive and Negative Syndrome Scale) positive subscale. Rowland et al. 82 scanned healthy subjects with ketamine and with placebo and observed an increase in Gln levels during the first 10 min of ketamine infusion. After 10 min, ketamine was administered in a lower maintenance dose and Gln levels normalized. No correlations were observed between SANS (Scale for the Assessment of Negative Symptoms) score and Gln levels. Taylor et al. 83 compared subjects who received ketamine with subjects who received placebo and reported no difference in Glx or Glu levels between these subject groups. Overall, these findings are consistent with findings of increased glutamatergic indices in MPFC in unmedicated patients with SCZ.
NMDA and SPECT One main limitation of glutamate 1 H MRS studies is that 1 H MRS provides a total tissue measure of neurochemicals and does not distinguish between intracellular or extracellular compartments, or between intra-or extrasynaptic compartments, further limiting the specificity of such measurements.
PET and SPECT allow for a more selective measurement of brain neurochemistry than does 1 H MRS. Although development of tracers for glutamatergic targets with suitable kinetic properties [84] [85] [86] and in a sample of healthy subjects after ketamine infusion. 87 Total distribution volume (V T ), a measure of both specific and nonspecific binding, was lower in all brain regions of clozapine medicated patients and in healthy subjects after treatment with ketamine except in putamen, temporal and pericallosal regions. The [
123 I]CNS-1261 BI 1 and BI 2 (measures of specific binding, similar to BP P and BP ND , 88 respectively, using whole cortex as a reference region) were lower in the left hippocampus of drug-free patients and in the right frontal lobe of clozapine-treated patients when compared with healthy control subjects. Higher specific binding was observed in the right cerebral regions (including occipital lobe) of clozapine-treated patients compared with healthy control subjects.
The results of these SPECT studies are consistent with the current understanding of the glutamate/NMDA hypothesis of SCZ that states that hypofunction of this system contributes to the etiology of SCZ. Although these data need to be replicated with additional, specific ligands, the field has recently been taking advantage of technological advances in brain imaging to examine additional parameters of the glutamate system, with a focus on neurochemicals that modulate the NMDAR, such as glycine and GSH.
NMDA RECEPTOR MODULATION
Background: NMDAR modulation NMDARs are activated by glutamate, which is the main excitatory neurotransmitter in the brain. NMDARs are modulated at two independent sites-a glycine/D-serine modulatory site and a proton (redox)-sensitive site (Figure 1 )-that therefore may serve as independent targets for pharmacological manipulation. The redox site is sensitive to compounds that modulate local pH and redox state, including polyamines and GSH. GSH (g-L-glutamyl-L-cysteinylglycine) is synthesized in brain from the amino acids cysteine, glutamate and glycine. The availability of cysteine is rate limiting for GSH synthesis. GSH is a nonprotein thiol that is the primary brain antioxidant and thus important in protecting the brain against oxidative stress.
3,89 When presented extracellularly, GSH or other reducing agents increase glutamate-induced depolarization via NMDAR activation, whereas extracellular oxidizing conditions decrease this response. 90 NAC is a prodrug of cysteine with high oral bioavailability and has primary effects as an antioxidant by stimulating the formation of GSH from cysteine. 3, 91 Disturbances of GSH metabolism have been linked to SCZ based upon several lines of evidence. Mice with a chronic deficit in GSH induced by knocking out the gene for the glutamate-cysteine ligase modulatory subunit demonstrated elevations in anterior cortical glutamate and glutamine levels that were similar to what is observed in unmedicated patients or early SCZ. 92 Treatment with NAC normalized these levels. 92 Experimentally induced GSH deficits in rodents lead to impairments in long-term potentiation and NMDAR dysfunction, 93 and may also contribute to cognitive deficits, suggesting a role of GSH depletion in cognitive impairments in SCZ. 94, 95 Finally, NAC, which is converted to GSH in vivo, has been used in one long-term clinical study of SCZ to date. In this study, Berk et al. 96 randomized 140 medicated patients with SCZ to either placebo or 1 mg NAC b.i.d. for 24 weeks. Patients who received NAC had greater improvements on the PANSS total, general and negative subscales, as well as on the CGI-S (Clinical Global Impression-Severity) scale (effects sizes 0.43-0.57).
Glutathione and 1 H MRS
Although GSH quantification with spectroscopy is challenging, evidence from 1 H MRS studies also supports a role for GSH in SCZ (Table 3) . Four studies have used 1 H MRS to measure GSH levels in the brains of individuals with SCZ and healthy control subjects. Using a PRESS (Point-RESolved Spectroscopy) sequence and the linear combination model for spectral analysis, increased levels of GSH were measured in the temporal lobe of a group of FE patients, some of whom were medicated 97 and no significant relationship was observed between GSH levels and PANSS total score. 97 Do et al. 98 used a double quantum coherence filter technique with PRESS and observed decreased levels of GSH in the MPFC of a heterogenous group of patients with SCZ. Matsuzawa et al. 99 used the MEGA-PRESS sequence to acquire GSH spectra and reported no difference in GSH levels in the posterior medial frontal cortex in atypical medicated chronic patients compared with healthy control subjects, although negative clinical correlations were observed between GSH levels and scores on total SANS, negative BPRS (Brief Psychiatric Rating Scale) and the Trail Making Test. Similarly, a study that used STEAM (STimulated Echo Acquisition Mode) spectroscopy revealed no difference in GSH levels in the ACC between chronic medicated patients and healthy control subjects. 100 In this study, Terpstra et al. 100 supported their findings by cross-validating their STEAM and MEGA-PRESS sequences.
Although the use of spectral fitting and sequences that utilize J-coupling (for example, MEGA-PRESS) produce robustly quantifiable spectra, other techniques for measuring GSH such as double quantum coherence filter have been validated. 101, 102 Therefore, the contribution of differences in sequences and spectral editing techniques to the discrepancies in the GSH literature remains unclear. In addition, other factors, such as medication status and phase of illness, may contribute to these different findings.
Although only a few studies have examined GSH levels in SCZ and the results are mixed, these results suggest abnormalities of GSH in SCZ. Future research should examine the effects of treatment on GSH levels in drug-naive/free subjects, as well as examine the effects of NAC challenge and ketamine challenge on GSH levels.
Glutathione and PET/SPECT PET 103 and SPECT 104 ligands for GSH and GSH transferase are being developed but remain in the preclinical stage of development. Furthermore, their penetration of the blood-brain barrier has not been established. Glutamate imaging in schizophrenia EMP Poels et al Glycine and PET/SPECT As described above, the NMDAR is modulated at both a redox site and a glycine/D-serine site (Figure 1 ). To date, promising clinical results have been obtained with compounds such as glycine, D-serine, sarcosine 5 and glycine transport inhibitors 6 that target the glycine site of the NMDAR. Although no MRS, PET or SPECT studies of the glycine transporter have been performed in SCZ, several PET tracers that target the glycine transporter type 1 (GlyT-1), such as [ ]MK-6577 is another promising GlyT-1 tracer but remains to be characterized in humans. 109, 110 An inherent problem for any radiotracer for this target is the lack of a reference tissue, that is, a brain region mostly devoid of GlyT-1 that can be used to estimate nonspecific binding. This limits the information that can be obtained from a single scan with any of these tracers to regional distribution volume, a parameter that is the sum of several terms, not all of which are related to GlyT-1 availability. 88 TYPE 5 METABOTROPIC GLUTAMATE RECEPTOR (MGLUR5) mGluR5 and SCZ Recent preclinical evidence suggests that targeting the mGluR5 may be an alternate and effective way of ameliorating NMDAR hypofunction in SCZ. mGluR5 belongs to group I of metabotropic receptors (mGluR1 and mGluR5) that signals via phospholipase C and potentiates NMDAR currents (Figure 2) , as opposed to group II and III receptors (mGlu2, 3, 4, 6, 7, 8 ) that tend to limit glutamate release (see review in refs. 111 and 112). mGluR5 is particularly implicated as a potentiator of NMDA function as agonists of either mGluR1 or mGluR5 potentiate NMDAR currents, but only an mGluR5 selective antagonist blocked this potentiation. 113, 114 Similarly, group I mGluR agonists only potentiated NMDAR effects in mGluR1 knockout mice, but not in mGluR5 knockout mice. 113, 114 The importance of mGluR5 receptors on NMDAR function is highlighted not only by their functional interconnection but also by their physical interconnection. The mGluR5 colocalizes with the NMDAR in pyramidal cells (Figure 1) . 115 Studies have shown that mGluR5 is coupled to the NMDAR via a protein complex including postsynaptic density protein (PDS95), shank and homer proteins.
116-118
Selective modulation of mGluR5 in preclinical models of SCZ has demonstrated potential as a therapeutic strategy. Treatment of rodents with selective, positive modulators of mGluR5 improves models of positive symptoms 119 and cognitive deficits, 120, 121 whereas inhibiting or knocking out the mGluR5 leads to negative symptoms 122 or cognitive deficits. 123 mGluR5 knockout mice also exhibit SCZ-like deficits in prepulse inhibition 124 that are not reversible with antipsychotic treatment. 125 Furthermore, phencyclidine-induced deficits in prepulse inhibition were potentiated in rats treated with MPEP (2-methyl-6-phenylethynylpyridine), an antagonist of the mGlu5 receptor. 124, 126 In sum, preclinical models suggest that mGluR5 may be a promising target for drug development in SCZ, as decreasing transmission through the mGluR5 appears to mimic some of the clinical phenomena of SCZ, whereas enhancing transmission appears to ameliorate these phenomena. Although studies in preclinical species are encouraging, few post-mortem studies comparing mGluR5 levels and expression in individuals with SCZ and healthy control subjects have been performed, and the results from these studies have been equivocal. 115 18 F]FPEB brings with it the possibility of directly investigating the mGluR5 system in SCZ and assessing its potential for drug development.
SUMMARY
The current glutamate model of SCZ suggests hypofunction of the NMDAR. This is supported by the 1 H MRS and PET/SPECT studies reviewed above. Namely, ketamine infusion in healthy control subjects results in increased amphetamine-induced dopamine release in striatum. In addition, chronic ketamine use leads to increased D 1 receptor availability in cortex, consistent with what is observed in SCZ, at least in some studies. The 1 H MRS studies have shown that ketamine infusion leads to increased cortical glutamate levels, likely compensation for acute NMDAR blockade and hypofunction. These findings are consistent with 1 H MRS studies of glutamatergic indices in SCZ in which glutamatergic levels are elevated in MPFC and basal ganglia in early-stage, drugnaive or drug-free patients. These findings are also supported by SPECT studies in which ketamine infusion in healthy control subjects led to decreases in NMDAR availability, as well as by studies in individuals with SCZ in which NMDAR availability was decreased in the hippocampus of drug-free patients. Together, these studies provide pathophysiologic support for the glutamate hypofunction model of SCZ, are consistent with preclinical glutamatergic models of SCZ and encourage further development of agents such as glycine, D-serine, glycine transport inhibitors, 6 and NAC 5 that increase the activity of NMDAR. The recent and rapid advances in 1 H MRS sequences and PET/ SPECT ligands have paved the way for a greater, more nuanced understanding of the glutamate system in SCZ. New ligands that target GSH, the GlyT and the mGluR5 hold promise for direct, in vivo measurements of these systems, which would provide critical information on the pathophysiology and neurobiology of SCZ. This knowledge would in turn allow the more rapid and efficient development of treatments that target these systems, analogous to how nuclear imaging studies demonstrated that the necessary threshold for D 2 /D 3 receptor occupancy for clinical effectiveness is B60-70%
136,137 and the threshold for extrapyramidal side effects is B80%.
137
For example, knowing that a given drug shown to be effective in preclinical glutamatergic models does indeed produce similar effects in humans would greatly assist in the development of that drug. One important implementation would be for experimental compounds that fail to treat symptoms. Demonstrating that such a compound engages the target would allow one to 'fail' both the compound and the model. Demonstrating that such a compound does not engage the target would suggest that a different strategy for engaging the target (for example, dose, compound) is necessary. Without a target engagement biomarker, there is no way of knowing whether the drug simply does not get into the brain in sufficient concentration to be effective in humans, or whether the overall mechanism is wrong. An imaging-based glutamate system marker, for example, could be critical in assessing whether a recent trial of a mGluR2/3 agent in SCZ 138 was inadequately dosed to engage the glutamate system in patients, or whether it may have failed despite engaging its target (that is, mGluR2/3); these questions are not answered by the knowledge that this agent demonstrated target engagement in a preclinical model.
Advances in MRS technologies, as well as the development of new PET ligands capable of imaging different components of the glutamate system, have opened the door for new opportunities to investigate this system in SCZ. Further investigation is critical and will facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments.
